Home » Stocks » PTGX

Protagonist Therapeutics, Inc. (PTGX)

Stock Price: $28.67 USD -0.51 (-1.75%)
Updated May 10, 2021 3:15 PM EDT - Market open
Market Cap 1.28B
Revenue (ttm) 31.17M
Net Income (ttm) -70.07M
Shares Out 43.95M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $28.67
Previous Close $29.18
Change ($) -0.51
Change (%) -1.75%
Day's Open 28.95
Day's Range 28.07 - 30.09
Day's Volume 78,489
52-Week Range 13.54 - 32.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

NEWARK, Calif., May 4, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first quarter of 2021 ended March 31, 2021 a...

5 days ago - PRNewsWire

NEWARK, Calif., May 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hir...

6 days ago - PRNewsWire

NEWARK, Calif., April 27, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (Nasdaq: PTGX), today announced the completion of enrollment for the Company's Phase 2 stud...

1 week ago - PRNewsWire

NEWARK, Calif., March 22, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that the Division of Nonmalignant Hematology at the U.S. Food and ...

1 month ago - PRNewsWire

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...

1 month ago - Zacks Investment Research

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -2.13% and 67.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

NEWARK, Calif., March 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (Nasdaq: PTGX) today reported financial results and provided a corporate update for the fou...

1 month ago - PRNewsWire

NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to...

2 months ago - PRNewsWire

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

NEWARK, Calif., Feb. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recently...

2 months ago - PRNewsWire

NEWARK, Calif., Jan. 29, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's r...

3 months ago - PRNewsWire

NEWARK, Calif., Jan. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the 39th An...

4 months ago - PRNewsWire

Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.

4 months ago - Zacks Investment Research

NEWARK, Calif., Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-7724...

4 months ago - PRNewsWire

NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwrit...

4 months ago - PRNewsWire

NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwrit...

4 months ago - PRNewsWire

NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offe...

5 months ago - PRNewsWire

NEWARK, Calif., Dec. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera, de...

5 months ago - PRNewsWire

NEWARK, Calif., Dec. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with polycythem...

5 months ago - PRNewsWire

NEWARK, Calif., Nov. 30, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Co...

5 months ago - PRNewsWire

NEWARK, Calif., Nov. 25, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fire...

5 months ago - PRNewsWire

NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fires...

5 months ago - PRNewsWire

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 65.57% and 245.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

6 months ago - Zacks Investment Research

NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate u...

6 months ago - PRNewsWire

NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology...

6 months ago - PRNewsWire

NEWARK, Calif., Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration ag...

6 months ago - PRNewsWire

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

NEWARK, Calif., Oct. 21, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for PTG-300 in the...

6 months ago - PRNewsWire

NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fire...

7 months ago - PRNewsWire

NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

7 months ago - PRNewsWire

NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

7 months ago - PRNewsWire

NEWARK, Calif., Sept. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

8 months ago - PRNewsWire

NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.

8 months ago - PRNewsWire

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Other stocks mentioned: BMY, KDMN
10 months ago - Investors Business Daily

Why Protagonist Should Be On Your Radar After Latest Trial Update

10 months ago - Seeking Alpha

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.

10 months ago - Zacks Investment Research

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-3...

10 months ago - PRNewsWire

NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fires...

10 months ago - PRNewsWire

Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning

11 months ago - Seeking Alpha

NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-t...

11 months ago - PRNewsWire

NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming...

11 months ago - PRNewsWire

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Here's what's behind their impressive market performances.

Other stocks mentioned: MGNX, STML
11 months ago - The Motley Fool

Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.

1 year ago - Zacks Investment Research

Why is Protagonist Therapeutics (PTGX) Soaring 90% Today?

YouTube video

zacks.com zacks.com/ultimate

1 year ago - Zacks Investment Research

The company is set to start a pivotal study for one of its lead pipeline candidates.

1 year ago - The Motley Fool

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About PTGX

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's ... [Read more...]

Industry
Biotechnology
IPO Date
Aug 11, 2016
Stock Exchange
NASDAQ
Ticker Symbol
PTGX
Full Company Profile

Financial Performance

In 2020, PTGX's revenue was $28.63 million, an increase of 12,293.07% compared to the previous year's $231,000. Losses were -$66.15 million, -14.30% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is 37.40, which is an increase of 30.45% from the latest price.

Price Target
$37.40
(30.45% upside)
Analyst Consensus: Buy